Psychedelics show comparable efficacy to antidepressants, but systemic barriers hinder equitable access
Original framing: “Psychedelics may be no better than antidepressants for depression” — New Scientist
The original framing omits the role of trauma-informed care, the potential of psychedelic-assisted therapy in addressing systemic mental health disparities, and the historical criminalization of psychedelics that has suppressed their therapeutic use. It also ignores the contributions of Indigenous knowledge systems in psychedelic healing.
Low structural omission detected in mainstream coverage.
This narrative is produced by mainstream science journalism, primarily for a Western, English-speaking audience. It reinforces the biomedical paradigm that marginalizes alternative and indigenous healing systems. The framing serves pharmaceutical and regulatory interests by normalizing antidepressants while downplaying the need for policy reform around psychedelic therapies.
The criminalization of psychedelics in the 20th century was driven by political and moral panic, not scientific evidence. This history continues to shape current regulatory barriers to research and treatment.
The comparative efficacy of psychedelics and antidepressants is not the central issue—what matters is the systemic exclusion of alternative healing modalities from mainstream mental health care.